clofibric acid has been researched along with Arteriosclerosis Obliterans in 1 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 7.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 3.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dembińska-Kieć, A | 1 |
| Kostka-Trabka, E | 1 |
| Grodzińska, L | 1 |
| Bieroń, K | 1 |
| Kedzior, A | 1 |
| Basista, M | 1 |
| Zmuda, A | 1 |
| Trabka, E | 1 |
| Slawiński, M | 1 |
| Czarnecka, H | 1 |
1 other study available for clofibric acid and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Topics: Adult; Arteriosclerosis Obliterans; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hy | 1989 |